The Viennalab RealFast™ Assays for HLA-A31:01 and HLA-B15:02 alleles provide a reliable and efficient way to prevent severe hypersensitivity reactions in patients prescribed carbamazepine. Carbamazepine can cause severe hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and severe drug reaction with eosinophilia and systemic symptoms (DRESS) in approximately 5% to 10% of individuals.
The prevalence of HLA-B15:02 can be as high as 25% in many Asian populations, and this allele is strongly associated with carbamazepine-induced SJS/TEN. The HLA-A31:01 allele is associated with a wider range of carbamazepine-induced hypersensitivity in diverse populations. Genotyping patients prior to starting therapy can significantly reduce the incidence of severe hypersensitivity reactions.
Product Notes
Instructions for Use
Brochures
MSDS
Looking for a reliable and efficient way to prevent severe hypersensitivity reactions in patients prescribed carbamazepine? Look no further than the Viennalab RealFast™ Assays for HLA-A31:01 and HLA-B15:02 alleles! Our assays accurately discriminate between the presence or absence of these variant alleles, providing a crucial tool for preventing adverse reactions.
In approximately 5% to 10% of individuals, carbamazepine can cause severe hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and severe drug reaction with eosinophilia and systemic symptoms (DRESS). The prevalence of HLA-B15:02 can be as high as 25% in many Asian populations, and this allele is strongly associated with carbamazepine-induced SJS/TEN. On the other hand, the HLA-A31:01 allele is associated with a wider range of carbamazepine-induced hypersensitivity in diverse populations.
The Clinical Pharmacogenetic Implementation Consortium (CPIC) recommends excluding patients carrying the HLA-A31:01 or HLA-B15:02 allele from carbamazepine therapy, and the FDA recommends testing for HLA-B*15:02 in patients treated with carbamazepine. By genotyping patients prior to starting therapy, you can significantly reduce the incidence of severe hypersensitivity reactions.
Trust in the Viennalab RealFast™ Assays for HLA-A31:01 and HLA-B15:02 genotyping to provide you with accurate and reliable results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!
The kit also includes instructions for use, as well as a protocol for the detection of HLA-A3101 and HLA-B1502 alleles using real-time PCR.
Goffin Molecular Technologies is a leading Dutch company with a rich history, offering a diverse range of high-quality molecular diagnostics products from various manufacturers.
